Synapse Open Synapse
Biology

Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

Nature Medicine · · 42 min read

As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.

Latest from Nature Medicine